The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Julian Harrison - BTIG - Analyst
: Hi, Congrats on the quarter and thank you for taking question. First, I'm curious if you're seeing any changes in YUPELRI prescribing patterns post
ensifentrine launch, either headwinds or tailwinds there? And then second, can you remind us where you stand on site activations for the CYPRESS
study? Are you at target now? If not, how far away are you from that?
Question: Julian Harrison - BTIG - Analyst
: Excellent. Thank you and congrats again.
Question: Ernie Rodriguez - TD Cowen - Analyst
: Hi team. Congratulations on your record quarter. Thanks for taking our question. I start with, for YUPELRI, you mentioned the hospital doses sold
increased by 40% year-to-year, and you also are increasing your market share. Could you give us more color on what's driving that and what the
Question: Ernie Rodriguez - TD Cowen - Analyst
: Got it. Thank you. That's very useful. And then just another quick question on the committee, the newly formed committee to, that's assessing the
strategic alternatives. What prompted the initiative? I guess, why now? And what would be the ideal outcome of options that you'd consider?
Question: Ernie Rodriguez - TD Cowen - Analyst
: Yes. No, that's very helpful. Thank you for that and congrats again on the quarter.
Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst
: Hi, good afternoon. Thanks for taking the questions. So apologies in advance if this question has already been asked. But just curious, it looked like
we sort of started to have a nice rebound with YUPELRI this quarter, certainly coming in ahead of our expectations. Just curious the extent that you
were able to make progress in terms of impacting the ASP and what that might mean for expectations heading into 2025. Thank you.
Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst
: No, no. I was going to say, Rick, I mean, so obviously, Rhonda, as you noted, there is a lag in terms of the reported ASP and that obviously affects
what you're able to command in certain channels. But I'm just curious in terms of the sort of receptivity or impact on the customer base as you sort
of try to pursue these initiatives and whether you experienced any resistance or were you able to sort of implement them without any kind of
disruption from a volume standpoint? Or ruffling feathers is perhaps the better way to put it.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 12, 2024 / 10:00PM, TBPH.OQ - Q3 2024 Theravance Biopharma Inc Earnings Call
Rhonda Farnum - Theravance Biopharma Inc - Senior Vice President - Commercial and Medical Affairs, Chief Business Officer
Yes. Well, it's always the goal to not ruffle feather. So I would say, I would answer to the latter is the situation.
Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst
: Okay, great. Thank you.
| 
